Oropharyngeal Neoplasms Clinical Trial
Official title:
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to reduce the overall amount of radiation given and decrease the amount of side effects you may experience.
Primary Objectives To determine whether: 1. Omission of the contralateral neck cancer treatment is safe and toxicity-sparing for participants with well lateralized oropharyngeal HNSCC undergoing definitive or PORT radiation. This will be demonstrated by acceptably low contralateral neck failures (<15%) Secondary Objectives To determine: 1. the relative difference in symptom burden, as measured by the MDASI_HN area-under-the-toxicity curve (AUC), for initial surgical and initial non-surgical therapy cohorts. 2. Whether omission of the contralateral neck in radiotherapy planning as definitive of PORT treatment for well-lateralized oropharyngeal tumors will impact symptom burden as measured by MDASI AUC, Grade 2 or higher CTCAE v5.0 toxicity, swallow function, and/or feeding tube rates and dependency. 3. Risk adapted therapy approaches lead to differences in distant-metastasis-free survival (DMFS), ipsilateral neck failure, primary site failure, and whether salvage therapy for contralateral neck failures is feasible and effective compared to historical controls. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03239834 -
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
|
||
| Recruiting |
NCT00251381 -
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
|
Phase 2 | |
| Completed |
NCT03074110 -
Isocapnic Hyperventilation - an Alternative Method
|
N/A | |
| Enrolling by invitation |
NCT04266093 -
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
|
||
| Recruiting |
NCT02792322 -
Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck
|
N/A | |
| Active, not recruiting |
NCT00918710 -
Human Papillomavirus and Oropharynx Carcinoma
|
N/A | |
| Recruiting |
NCT05412628 -
Investigating the Association Between Microbiota and Esophageal/Oropharyngeal Cancer
|
N/A | |
| Recruiting |
NCT04124198 -
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
|
N/A | |
| Completed |
NCT00721799 -
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT00181038 -
Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
|
Phase 3 | |
| Terminated |
NCT04015336 -
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
|
Phase 2 | |
| Withdrawn |
NCT04044950 -
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT02262247 -
A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures
|
N/A | |
| Terminated |
NCT01687413 -
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
|
Phase 3 | |
| Completed |
NCT01530997 -
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
|
Phase 2 | |
| Completed |
NCT03077243 -
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
|
Phase 2 | |
| Completed |
NCT03010813 -
A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery
|
N/A | |
| Terminated |
NCT02045186 -
Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
|
N/A | |
| Withdrawn |
NCT02298595 -
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02281955 -
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
|
Phase 2 |